

IPR & Innovation

Lalit Bhasin: For 'Make in India', first 'Innovate in India', [Business Standard](#)

Undoubtedly, India has all the essential elements for a successful 'Make in India' programme - a large young and skilled workforce, an enabling economic environment and competitive wages. Under the policies of the current government, India's manufacturing capacity for innovation and infrastructure is poised for phenomenal growth.

There is empirical evidence

Study suggests panobinostat and similar gene regulating drugs may be effective to treat lethal paediatric, [Pharmabiz.com](#)

Using brain tumour samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), an aggressive and lethal form of paediatric cancer. The study, published in Nature

Patent pressures, [The Hindu](#)

business (general) In its 2015 Special 301 Report on Intellectual Property Rights, the office of the United States Trade Representative (USTR) has retained India in its Priority Watch List, noting however that bilateral engagement between the two countries on IPR concerns had increased over the past year. The USTR had

US Pharma Sector Welcomes India's Intellectual Property Policy, [Outlook India](#)

The US pharma sector has welcomed India's recent moves on intellectual property, including bringing out a draft policy and sustained engagement, while regretting the consistent barriers posed by the country's pharma sector to US companies.

Acknowledging the "measured and cautious approach" of India in responding to recent requests for compulsory licenses

Similar reports have appeared in:

[The Economic Times](#)

Access to Healthcare

Leprosy: antiquated Indian laws breed stigma, discrimination, [The Hindu](#)

No less dreaded and stigmatised than HIV/AIDS, leprosy, sadly, has been off the priority list of the successive governments for a long time. Worse, the rights of those affected by leprosy and their families, in India and elsewhere, continue to be violated even now.

TB treatment programme may be generating more MDR cases, [The Hindu](#)

The RNTCP currently treats patients without knowing their resistance profile: JMM

The Joint Monitoring Mission 2015 has come down heavily on the Revised National Tuberculosis Control Programme (RNTCP) and the Ministry of Health and Family Welfare for their inability to handle the MDR-TB crisis in the country. The report released last

Medical & Regulatory

SHRC to hear complaints on drug prescriptions, [The Hindu](#)

The Kerala State Human Rights Commission (SHRC) has directed the Health Secretary to submit a report after investigating a complaint that indecipherable medical prescriptions of doctors are making it difficult for medical stores to read the names of the drugs prescribed. A release issued by the KSHRC on Wednesday said commission

BDCDA seeks clarity on online trade as MedPlus launches booking for medicines online at lower prices, [Pharmabiz.com](#)

The Bangalore District Chemists and Druggists Association (BDCDA) is urging Karnataka drugs control department to provide clarity on whether retail drug licenses obtained as per the Drugs and Cosmetics Act and Rules can do online sales and home delivery of medicines to customers. This follows the recent advertisements by the Hyderabad-based

Cough syrup bottles seized in Baddi, [The Tribune](#)

Tribune News Service Solan, May 6 As many as 277 bottles of various cough syrups and more than 21,628 capsules and tablets of sedative drugs were seized by a team of Baddi police last night from the house of a chemist at Kattiwala village near Baddi. Jasbir Singh runs a chemist

Pharma Transparency in Brazil: Latest Developments, [Pharmaceutical Executive](#)

By Scott Lewin Scott Lewin looks at Brazil's recently expanded transparency initiatives and how they affect pharma companies doing business in the region. Brazil, the market leader for pharmaceuticals in Latin America, continues its economic transformation as the region's most prominent manufacturing, packaging and distribution hub. Building upon its economic makeover

Generon gets US FDA nod to begin phase IIa study of F-652 to treat patients with acute GvHD, [Pharmabiz.com](#)

The US Food and Drug Administration (FDA) has granted clearance to Generon Corporation's Investigational New Drug (IND) application for a phase IIa study, entitled "Recombinant Human Interleukin-22-IgG2-Fc (F-652) in combination with systemic corticosteroids for the treatment of newly diagnosed grade II-IV lower gastrointestinal acute graft-versus-host disease in hematopoietic stem cell

Gujarat, Karnataka also detect cases of illegal online sales of prescription drugs, [Pharmabiz.com](#)

Against the backdrop of cases of violation to Drugs & Cosmetics Act for online sales of prescription drugs by e-commerce websites, Gujarat Food and Drug Control Administration (FDCA) has till date detected three such cases of online sales of prescription drugs and spurious medicines. The regulator has taken legal action

Kadmon begins second phase 2 trial evaluating KD026 in type 2 diabetes, [Pharmabiz.com](#)

Kadmon Corporation, LLC, a vertically integrated biopharmaceutical company, announced that the first patient has been dosed in its second phase 2 clinical trial (Study KD026-201) evaluating the safety, tolerability and efficacy of KD026, inhibitor of microsomal triglyceride transfer protein (MTP), in combination with metformin in patients with type 2 diabetes

NIH-funded study shows way forward for retinal disease gene therapy, [Pharmabiz.com](#)

Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes vision loss starting in childhood, improved patients eyesight and the sensitivity of the retina within weeks of treatment. Both of these benefits, however, peaked one to three years after treatment and then diminished, according to results from an

ViiV/J&J HIV maintenance combo moves into PhIII, [PharmaTimes](#)

ViiV Healthcare has kicked off a Phase III clinical trial programme to assess the safety and efficacy of a new combination maintenance therapy for adult patients with HIV.

The single tablet combines ViiV's integrase inhibitor Tivicay (dolutegravir) with Johnson & Johnson's non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine).

The Phase III programme is

Other News on Pharma

Alexion to bolster rare disease offering with \$8.4 billion deal, [Business Standard](#)

By Vidya L Nathan, Natalie Grover and Bill Berkrot

(Reuters) - Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for \$8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases.

Alexion's willingness to pay an eye-popping premium for

Similar reports have appeared in:

[Firstpost.com](#)

GlaxoSmithKline targets growth across units, scraps ViiV listing, [Business Standard](#)

By Ben Hirschler

LONDON (Reuters) - GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth.

It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook, and

Similar reports have appeared in:

[The Economic Times](#)

Performance Driven IT Solutions Critical to Reduce Fragmentation in Australia's Healthcare System: F, [The Telegraph](#)

SYDNEY , May 7, 2015 /PRNewswire/ -- In comparison to other Asia-Pacific (APAC) countries or the US and Europe , Australia's healthcare system allows easy access and provides quality care.

However, as of 2014, of all APAC countries, Australia had the highest healthcare expenditure at AUD\$6,400 per capita, per annum,

Taiwan's Apex Medical forays into Indian healthcare market, [The Hindu Business Line](#)

Taiwan's Apex Medical Corp is foraying into India to tap the growing healthcare market and plans to initially invest â,100 crore to market quality and affordable equipment to hospitals and nursing homes.

The \$75-million company plans to launch its products through Apex Medical India in the field of respiratory therapy, such

Similar reports have appeared in:

[Pharmabiz.com](#)
